Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M 

June 16, 2022  |  Startland News Staff

Dr. F. Nicholas Franano, Artio Medical; photo courtesy of Max McBride

Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.

Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.

Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.

Click here to read more about Artio’s $12 million funding infusion in 2021. 

“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.

“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.” 

Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.

Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.

Click here to learn more about Artio’s portfolio of products.

startland-tip-jar

TIP JAR

Did you enjoy this post? Show your support by becoming a member or buying us a coffee.

Tagged , , ,
Featured Business
    Featured Founder

      2022 Startups to Watch

        stats here

        Related Posts on Startland News

        Ahead of Valentine’s, e-commerce floral shop Zinnia prunes itself to grow

        By Tommy Felts | February 9, 2016

        Zinnia is not your mom-and-pop local florist — although the company did have a brief iteration as one lasting about a blink last year. It’s also not your big-box, online flower retailer — although their ecommerce site is a beautiful example of what a website focused on the customer experience can look like. The company…

        LaunchKC delivering another $500K in 2016

        By Tommy Felts | February 8, 2016

        Kansas City’s popular grant competition, LaunchKC, will be doling out another $500,000 in 2016 to startups around the world. LaunchKC in April will open the application period for its international competition, which will issue ten $50,000 grants to winners during the second-annual Techweek Kansas City conference. Drew Solomon, vice president of business and job development…

        Key legislator optimistic in the future of Kansas’ angel tax credits

        By Tommy Felts | February 5, 2016

        A Kansas lawmaker overseeing discussion on the future of the state’s angel investor tax credits is confident the program will be made a budgetary priority by his peers in legislature. Rep. Marvin Kleeb, R-Overland Park, said that he and fellow members of the Kansas Committee on Taxation listened to thorough testimony Wednesday during a hearing…

        5 reasons your startup isn’t attracting investors

        By Tommy Felts | February 4, 2016

        Last week, Techstars managing director John Fein told us that one of the main complaints he hears from Kansas City investors is that there aren’t enough fundable startups. Investors may be right, but it’s not necessarily a lack of good ideas. Today, Kansas City investors are looking for more than the next big idea: they’re…